echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > More than half of the patients achieved complete remission. "Ready-to-use" NK cell therapy has positive early clinical results

    More than half of the patients achieved complete remission. "Ready-to-use" NK cell therapy has positive early clinical results

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Fate Therapeutics announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting that it announced its research on natural killer cell (NK cell) therapy FT516, combined with rituximab, to treat patients with relapsed/refractory B-cell lymphoma.


    As of March 11, 2021, a total of 11 patients can be used for safety and efficacy assessment


    Picture source: reference [1]

    In terms of safety, no dose-limiting toxicity was found, no serious adverse events related to FT516 and adverse events above grade 3 related to FT516 were found


    Note: The original text has been deleted

    Reference materials:

    [1] Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.